HBIO HARVARD BIOSCIENCE INC

Nasdaq harvardbioscience.com


$ 0.42 $ 0.00 (-0.26 %)    

Tuesday, 14-Oct-2025 15:57:20 EDT
QQQ $ 602.94 $ 0.00 (0 %)
DIA $ 464.69 $ 0.00 (0 %)
SPY $ 666.51 $ 0.00 (0 %)
TLT $ 91.04 $ 0.00 (0 %)
GLD $ 386.68 $ 0.00 (0 %)
$ 0.4206
$ 0.42
$ 0.35 x 200
$ 0.60 x 625
-- - --
$ 0.28 - $ 2.82
365,331
na
18.73M
$ 1.40
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-11-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-13-2025 12-31-2024 10-K
4 11-08-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 03-07-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 04-26-2023 03-31-2023 10-Q
11 03-09-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-04-2022 03-31-2022 10-Q
15 03-11-2022 12-31-2021 10-K
16 11-05-2021 09-30-2021 10-Q
17 08-06-2021 06-30-2021 10-Q
18 05-07-2021 03-31-2021 10-Q
19 03-12-2021 12-31-2020 10-K
20 11-06-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-08-2020 03-31-2020 10-Q
23 03-16-2020 12-31-2019 10-K
24 11-08-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-08-2019 03-31-2019 10-Q
27 03-18-2019 12-31-2018 10-K
28 11-01-2018 09-30-2018 10-Q
29 08-02-2018 06-30-2018 10-Q
30 05-10-2018 03-31-2018 10-Q
31 03-16-2018 12-31-2017 10-K
32 11-02-2017 09-30-2017 10-Q
33 08-03-2017 06-30-2017 10-Q
34 05-08-2017 03-31-2017 10-Q
35 03-17-2017 12-31-2016 10-K
36 11-03-2016 09-30-2016 10-Q
37 08-04-2016 06-30-2016 10-Q
38 05-16-2016 03-31-2016 10-Q
39 04-29-2016 12-31-2015 10-K
40 11-05-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 harvard-bioscience-granted-180-days-or-until-march-30-2026-by-nasdaq-for-compliance

- SEC Filing

 benchmark-maintains-speculative-buy-on-harvard-bioscience-lowers-price-target-to-2

Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price ta...

 harvard-bioscience-enters-sixth-amendment-to-credit-agreement-lenders-agree-not-to-test-financial-covenants-for-q3-2025-agrees-to-pay-400k-fees-to-lenders-explores-alternative-capital-sources-for-refinancing-says-there-is-substantial-doubt-about-cos-ability-to-continue-as-a-going-concern

Item 1.01. Entry into a Material Definitive Agreement. On August 8, 2025, Harvard Bioscience, Inc. (the "Company") ente...

 harvard-bioscience-sees-q3-sales-19000m-21000m-vs-2175m-est

Harvard Bioscience (NASDAQ:HBIO) sees Q3 sales of $19.000 million-$21.000 million vs $21.75 million analyst estimate.

 harvard-bioscience-q2-adj-eps-001-inline-sales-2045m-beat-2040m-estimate

Harvard Bioscience (NASDAQ:HBIO) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. The ...

 benchmark-maintains-speculative-buy-on-harvard-bioscience-lowers-price-target-to-3

Benchmark analyst Bruce Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price targe...

 harvard-bioscience-sees-q2-sales-18000m-20000m-vs-1920m-est

Harvard Bioscience (NASDAQ:HBIO) sees Q2 sales of $18.000 million-$20.000 million vs $19.20 million analyst estimate.

 harvard-bioscience-q1-adj-eps-001-beats-004-estimate-sales-2177m-beat-1920m-estimate

Harvard Bioscience (NASDAQ:HBIO) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION